NASDAQ · IXHL
Healthcare · Drug Manufacturers - Specialty & Generic
$3.57
Down-$0.05 (-1.38%)
Updated Aug 23, 2026, 9:40 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IXHL closed at $3.57 after 20 trading sessions, up 19.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.62 | $3.65 | $3.5136 | $3.57 | 71.45K |
| Aug 20, 2026 | $3.38 | $3.62 | $3.35 | $3.62 | 76.88K |
| Aug 19, 2026 | $3.35 | $3.47 | $3.30 | $3.44 | 100.48K |
| Aug 18, 2026 | $3.31 | $3.44 | $3.25 | $3.36 | 101.77K |
| Aug 17, 2026 | $3.30 | $3.3799 | $3.24 | $3.315 | 78.43K |
| Aug 14, 2026 | $3.184 | $3.29 | $3.16 | $3.28 | 100.65K |
| Aug 13, 2026 | $3.20 | $3.2319 | $3.13 | $3.16 | 72.92K |
| Aug 12, 2026 | $3.16 | $3.22 | $3.09 | $3.17 | 74.8K |
| Aug 11, 2026 | $3.30 | $3.30 | $3.135 | $3.20 | 101.38K |
| Aug 10, 2026 | $3.12 | $3.25 | $3.12 | $3.23 | 85.03K |
| Aug 7, 2026 | $3.1344 | $3.24 | $3.11 | $3.155 | 101.95K |
| Aug 6, 2026 | $3.04 | $3.15 | $3.0201 | $3.11 | 74.3K |
| Aug 5, 2026 | $3.00 | $3.09 | $2.97 | $3.08 | 79.11K |
| Aug 4, 2026 | $3.01 | $3.04 | $2.93 | $2.97 | 113.63K |
| Aug 3, 2026 | $2.94 | $3.115 | $2.91 | $2.93 | 157.46K |
| Jul 31, 2026 | $2.96 | $3.00 | $2.82 | $2.94 | 71.72K |
| Jul 30, 2026 | $2.84 | $2.98 | $2.8201 | $2.93 | 74.27K |
| Jul 29, 2026 | $2.96 | $3.00 | $2.83 | $2.91 | 96.11K |
| Jul 28, 2026 | $3.00 | $3.02 | $2.85 | $2.96 | 66.32K |
| Jul 27, 2026 | $2.98 | $3.08 | $2.96 | $2.985 | 89.11K |
The latest Smart Investors Daily articles mentioning IXHL.
IXHL research
Company profile and research snapshot.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Alliance Global Partners | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$11.2 million in non-dilutive capital during 2026. The receipt further enhances Incannex’s already strong cash position
Benzinga · Jul 23, 2026
First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast Track designation,
Benzinga · Jun 25, 2026
The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline
Benzinga · Jun 10, 2026
Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IXHL.
